Zobrazeno 1 - 10
of 19
pro vyhledávání: '"FRANCOIS BRIAND"'
Publikováno v:
Diabetes. 71
Introduction: Combination of therapies is a promising strategy for the treatment of NASH and liver fibrosis. Here we evaluated whether the Farnesoid X Receptor agonist obeticholic acid (OCA) combined with the glucagon-like peptide-1 (GLP-1) receptor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::acd408844a41fbf00f3e9f9e8d0661bf
https://doi.org/10.2337/db22-272-or
https://doi.org/10.2337/db22-272-or
Publikováno v:
Nephrology Dialysis Transplantation. 37
BACKGROUND AND AIMS Beyond the glucose control, anti-diabetic drugs need to demonstrate benefits on metabolic comorbidities. An animal model that recapitulates obesity and type 2 diabetes (T2D) comorbidities [i.e. non-alcoholic steato-hepatitis (NASH
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0cda455d3e8bfa23001eebf446964219
https://doi.org/10.1093/ndt/gfac076.008
https://doi.org/10.1093/ndt/gfac076.008
Autor:
Francois Briand, Masami Shinohara, Emmanuel Brousseau, Julie Maupoint, Caroline Dubroca, Yasushi Kageyama, Thierry Sulpice
Publikováno v:
Nephrology Dialysis Transplantation. 37
BACKGROUND AND AIMS The Glucagon-like peptide 1 (GLP-1) receptor agonist liraglutide (LIRA) has cardioprotective effects and may reduce the development of kidney disease in type 2 diabetic patients. We here evaluated the effects of LIRA on both kidne
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3413f8b0717b2578fdaaaa2e7962fb80
https://doi.org/10.1093/ndt/gfac076.010
https://doi.org/10.1093/ndt/gfac076.010
Publikováno v:
Arteriosclerosis, Thrombosis, and Vascular Biology. 42
Background: Obesity, non-alcoholic steatohepatitis (NASH) and dyslipidemia have been associated with severe forms of COVID-19. To better understand the impact of SARS-CoV-2 infection on dyslipidemia and NASH, we investigated the impact of infection w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b1f9bf99f4543f9d88a6b001392dce7b
https://doi.org/10.1161/atvb.42.suppl_1.112
https://doi.org/10.1161/atvb.42.suppl_1.112
Publikováno v:
Journal of Hepatology. 77:S717
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9eb83a29ebbb550baee43fdec4e7f71b
https://doi.org/10.1016/s0168-8278(22)01752-4
https://doi.org/10.1016/s0168-8278(22)01752-4
Autor:
François Briand
Le Baron Haussmann a lancé ses grands travaux qui vont transformer la ville en profondeur et pour longtemps. Napoléon III règne depuis cinq ans, la France développe son industrie. Charles Gassier, un jeune homme de 18 ans, qui ne rêve que de lec
Autor:
François Briand
Michel, sans domicile fixe, vit à Rennes. Un jour, alors qu'il fait la manche, il est témoin d'une scène étrange : il voit un homme sortir d'un grand magasin en courant, un couteau à la main. Plus tard, il apprend qu'une vendeuse a été tuée.
Publikováno v:
Journal of Hepatology. 70:e521-e522
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::13e5d63105f7eecae61528ba0b659e84
https://doi.org/10.1016/s0618-8278(19)31030-8
https://doi.org/10.1016/s0618-8278(19)31030-8
Autor:
François Briand
La vie d'un écrivain oublié dans les tréfonds du passé...On a tous un jour tapé notre nom sur un moteur de recherches, juste pour voir. Pour ma part, j'y ai trouvé un : François Briand poète français actif au XVe siècle. Il y est ajouté qu
Autor:
Maxime Nachit, Christopher Montemagno, Romain Clerc, Mitra Ahmadi, François Briand, Sandrine Bacot, Nick Devoogdt, Cindy Serdjebi, Catherine Ghezzi, Thierry Sulpice, Alexis Broisat, Isabelle A. Leclercq, Pascale Perret
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-12 (2023)
Here, the authors present a noninvasive tool to detect liver inflammation using nuclear imaging, as an alternative to biopsy. The prove the diagnostic power of this tool to detect liver inflammation in preclinical models of chronic liver disease.
Externí odkaz:
https://doaj.org/article/d88758d761954f49a5f4a5060910e50c